🔴 Summit Therapeutics is trading 5.83% down today despite Akeso’s third NMPA approval

Summit Therapeutics is trading 5.83% down now at $14.22, with no reliable company-specific negative catalyst identified for the August 13 decline.

• Partner Akeso received China’s third NMPA approval for ivonescimab on August 12, 2026, covering first-line advanced squamous non-small-cell lung cancer alongside chemotherapy.
• The broader market is rising, so macro sentiment does not explain the move.